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Abstract Through an international consortium, we have
collected 37 tau- and TAR DNA-binding protein 43 (TDP-
43)-negative frontotemporal lobar degeneration (FTLD)
cases, and present here the first comprehensive analysis of
these cases in terms of neuropathology, genetics, demo-
graphics and clinical data. 92% (34/37) had fused in sarcoma
(FUS) protein pathology, indicating that FTLD-FUS is an
important FTLD subtype. This FTLD-FUS collection
specifically focussed on aFTLD-U cases, one of three recently
defined subtypes of FTLD-FUS. The aFTLD-U subtype of
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FTLD-FUS is characterised clinically by behavioural vari-
ant frontotemporal dementia (bvFTD) and has a particularly
young age of onset with a mean of 41 years. Further, this
subtype had a high prevalence of psychotic symptoms (36%
of cases) and low prevalence of motor symptoms (3% of
cases). We did not find FUS mutations in any aFTLD-U
case. To date, the only subtype of cases reported to have
ubiquitin-positive but tau-, TDP-43- and FUS-negative
pathology, termed FTLD-UPS, is the result of charged
multivesicular body protein 2B gene (CHMP2B) mutation.
We identified three FTLD-UPS cases, which are negative for
CHMP2B mutation, suggesting that the full complement of
FTLD pathologies is yet to be elucidated.
Keywords FTLD  FUS  FTLD-UPS  Frontotemporal 
FTD
Abbreviations
bvFTD Behavioural variant FTD
CHMP2B Charged multivesicular body protein 2B
FTD Frontotemporal dementia
FTD-3 FTD linked to chromosome 3
FTLD Frontotemporal lobar degeneration
FTLD-IF Frontotemporal lobar degeneration with
intermediate filament positive inclusions
FTLD-ni Frontotemporal lobar degeneration with no
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FTLD-TDP Frontotemporal lobar degeneration with
TDP-43 positive inclusions
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positive, TDP-43 negative inclusions
GRN Progranulin
MAPT Microtubule associated protein tau
NCI Neuronal cytoplasmic inclusion
NII Neuronal intranuclear inclusion
PPA Primary progressive aphasia
TDP-43 Transactive response binding protein of
43 kDa
VCP Valosin containing protein
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Introduction
Frontotemporal lobar degeneration (FTLD) describes a
group of diseases characterised by bilateral, often asym-
metric, atrophy of the frontal and anterior temporal lobes.
Frontotemporal dementia (FTD), also termed behavioural
variant FTD (bvFTD), is the most common clinical mani-
festation, but FTLD can also cause the language disorders
progressive non-fluent aphasia (PNFA) and semantic
dementia (SD), collectively known as primary progressive
aphasia (PPA). The clinical presentation is related to the
distribution of pathology in the frontal and temporal lobes.
Despite gross pathological similarities, FTLD comprises a
clinically, genetically, and neuropathologically heteroge-
neous collection of disorders.
A family history of a similar disease has been reported
in 25–40% of FTLD cases [6, 44, 50], although this
estimate is much lower in some populations [17]. FTLD-
causing mutations have been found in the microtubule-
associated protein tau (MAPT) [16], progranulin (GRN) [1, 7]
and charged multivesicular body protein 2B (CHMP2B)
genes [49]. Mutations in valosin-containing protein (VCP)
cause inclusion body myopathy and Paget disease of bone
with frontotemporal dementia, in which 20–100% of
patients can develop FTD [10, 53, 56]. GRN mutations
account for approximately 10% of FTLD cases [2, 7–9] and
MAPT up to 10% depending on the population studied
[15, 41, 48]; while mutations in CHMP2B are a much rarer
cause of FTLD, having been reported in one Danish family
termed frontotemporal dementia linked to chromosome 3
(FTD-3) [25, 49, 52] and one unrelated Belgian familial
FTLD patient [54].
Up to 40% of FTLD cases, including all MAPT mutation
cases, have tau pathology [48] (FTLD-tau); while over
50% have neuronal inclusions, which are immunoreactive
for ubiquitin in the absence of abnormal tau, a-synuclein,
or amyloid deposition [20]. In the majority of tau-negative
cases, the major ubiquitinated protein is the TAR DNA-
binding protein 43 (TDP-43) [11, 39], and these are
designated FTLD-TDP [30]. FTLD-TDP can be further
classified into neuropathological subtypes depending on the
distribution, morphology and precise cellular location of
inclusions [28, 45].
Recent studies report that 6–20% of tau-negative FTLD
cases have ubiquitinated inclusions which are TDP-43
negative [12, 21, 29, 42]. Ubiquitin positive, tau and TDP-
43 negative cases include those with neuronal intermediate
filament- and a-internexin-positive inclusions [5, 19],
termed NIFID, and basophilic inclusion body disease
(BIBD) [35, 58]. Distinct from these are a subset of FTLD
cases termed atypical FTLD-U (aFTLD-U), which do not
have intermediate filament positive or basophilic inclu-
sions, but are characterised by unusual curved or twisted
neuronal intranuclear ubiquitin positive inclusions, as well
as cytoplasmic inclusions [29, 42]. The recent finding of
FUS (fused in sarcoma) protein pathology in aFTLD-U
cases [37] and subsequently in NIFID and BIBD cases
[34, 38] has led to further reorganisation of FTLD classi-
fication [31]: aFTLD-U, NIFID and BIBD are now
considered three distinct subtypes of FTLD-FUS, the col-
lective term for FTLD cases with FUS pathology. Cases
with ubiquitinated inclusions that are negative for tau,
TDP-43 and FUS are termed FTLD-UPS [30]; this includes
FTLD cases caused by CHMP2B mutations [13, 14].
FUS pathology was first described in familial ALS cases
following the discovery of causative mutations in the FUS
gene [23, 55]. FUS is a multifunctional DNA- and RNA-
binding protein, sharing functional homology with TDP-43
[24]. FUS pathology has also been found in polyglutamine
expansion diseases including Huntington’s disease, sug-
gesting a broad spectrum of FUS proteinopathies [34, 38,
57]. However, FUS pathology was not found in FTD-3, a
major subtype of FTLD-UPS [14].
A minority of cases do not have tau, TDP-43, FUS or
ubiquitinated inclusions and these have been termed FTLD
with no inclusions (FTLD-ni, previously dementia lacking
distinctive histopathology, or DLDH) [30]. Increasingly
sensitive immunostaining protocols have led to most FTLD-
ni cases being reclassified [20, 26, 32]; however, a small
group remain negative for characterised inclusions despite
the use of updated ubiquitin immunohistochemistry.
Here, we report, through a major international collabo-
ration, the first comprehensive collection of the aFTLD-U
subtype of FTLD-FUS and describe their clinical and
demographic features.
Materials and methods
Cases
A total of 37 cases with ubiquitin-positive but tau- and
TDP-43-negative inclusions were evaluated from 12 aca-
demic research centres. In each centre, clinical information
was acquired from case notes by a neurologist with
expertise in neurodegenerative diseases. Standard neuro-
logical and cognitive assessments were used to ascertain
the presence of behavioural, cognitive and motor abnor-
malities. All centres followed consensus clinical criteria for
FTLD diagnosis [33, 36], and were asked to supply pre-
senting symptoms for each patient and the final clinical
diagnosis that had been rendered by the evaluating neu-
rologist. These data were collated and then reviewed by an
expert in FTLD (K.A.J.) to ensure consistency in diagnosis
among the different centres. BIBD and NIFID cases were
specifically excluded in order to focus on a specific subtype
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of FTLD-FUS. Twenty-three cases for which DNA was
available (21 FTLD-FUS and 2 FTLD-UPS) were screened
for CHMP2B mutations. Fifteen FTLD-FUS cases were
screened for FUS mutations and a further six have been
reported previously as FUS mutation negative [37]. Patients
were considered to have a family history if a first- or second-
degree relative had dementia. This study was approved by the
UCL Institute of Neurology and National Hospital for Neu-
rology and Neurosurgery Local Research Ethics Committee.
Histopathology
All cases were stained for TDP-43, ubiquitin and a-intern-
exin or neurofilament proteins according to local protocols
at each centre [2, 12, 21, 27, 29, 39, 40, 42, 47, 53]. Expe-
rienced neuropathologists in each centre analysed the
sections to give the neuropathological diagnosis. FUS
staining was subsequently performed on frontal cortex and
hippocampus for all cases. As previously described, FUS
staining is sensitive to length of fixation [37]. Therefore, at
least two antibodies (Sigma HPA008784 and Bethyl Labo-
ratories A300-302A) were used for all cases examined and
antibody concentrations optimised for each case by ensuring
physiological FUS staining was visible, as recommended in
the original description of FTLD-FUS [37]. To further
ensure inter-centre reliability 26 cases, including the three
remaining FTLD-UPS cases, were stained in one of two
laboratories which first reported FTLD-FUS (IRM or MN).
Genetic analysis
Genomic DNA was extracted from brain tissue using
standard phenol–chloroform extraction, or DNA extracted
from brain or blood was directly provided by the contrib-
utor. The entire open reading frame and exon–intron
boundaries of CHMP2B and FUS were sequenced, except
for three cases in which FUS exons 14 and 15 only were
sequenced. Primers and conditions for CHMP2B sequenc-
ing have been described previously [49]; conditions for
FUS sequencing are available on request. Sequences were
analysed using the SeqScape software Version 2.5
(Applied Biosystems, Foster City, CA, USA).
Results
Neuropathology
A total of 37 ubiquitin-positive, tau- and TDP-43-negative
cases were examined. 92% (34/37) of cases were charac-
terised by neuronal cytoplasmic and intranuclear inclusions
(NIIs) which were immunoreactive for FUS, corresponding
to the aFTLD-U subtype of FTLD-FUS. The NIIs were as
previously described, having an unusual morphology,
which can be long and straight, curved or twisted [29, 42].
Striatal degeneration was present in 100% (27/27) of
aFTLD-U cases and hippocampal sclerosis was present in
97% (29/30) of cases. 8% (3/37) were characterised by
ubiquitin-positive neuronal cytoplasmic inclusions (NCIs)
which were FUS-negative, i.e. FTLD-UPS.
Genetics
Sequencing of the CHMP2B gene in all cases for which
DNA was available revealed no further coding mutations.
Two synonymous coding variants were identified in three
FTLD-FUS cases: c.27C[T, p.Thr9Thr and c.372A[C,
p.Thr124Thr. These two variants were each observed in the
heterozygous state but always together, suggesting they
could be in linkage disequilibrium. None of these variants
has been previously reported, but as they do not lead to an
amino acid change, they are unlikely to be pathogenic.
Therefore, CHMP2B mutation-positive cases comprise a
distinct genetic subgroup of FTLD-UPS. No mutations were
identified in FUS in any case.
Demographics
Onset
Age at onset data was available for 33 aFTLD-U cases. The
mean age of onset was 41.2 years (standard deviation
9.3 years). The three FTLD-UPS cases had a mean age of
onset of 50.3 years (standard deviation 4 years).
Disease duration
Disease duration data were available for 33 aFTLD-U
cases. Mean disease duration was 7.7 years (standard
deviation 3.2 years). Disease duration data were available
for only two of the three FTLD-UPS cases and were 4 and
11 years, respectively.
Sex
Of the aFTLD-U cases, 47% (16/34) were female and all
three FTLD-UPS cases were female.
Family history
One aFTLD-U case (3%, 1/34) had a family history and 2/3
of the FTLD-UPS cases had positive family histories.
Clinical features
The clinical features of several aFTLD-U cases have pre-
viously been reported [21, 29, 42, 46] and analysed together,
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these cases form a clinically homogeneous group. 94% (32/
34) of aFTLD-U patients received an initial diagnosis of
bvFTD (Table 1). The other two patients, for whom there
was little clinical information available, were described as
having ‘unspecified dementia’. Patients were typically
described as showing a decline in social conduct, self-
neglect and disinhibition, with aggression as a common
feature. Inappropriate sexual behaviour was widely repor-
ted, in 52% of cases (12/23) (Table 1). Dietary changes,
most commonly overeating, were observed in 81% of cases
(21/26) with hyperorality a feature of several.
Strikingly, psychotic symptoms, either hallucinations or
delusions, were observed in 36% of aFTLD-U patients
(8/22), and not comorbid in any case. Motor symptoms
Table 1 Clinical symptoms in aFTLD-U cases
ID Sex Diagnosis Behavioural/personality Psychiatric Cognitive Motor
Apathy Disinh Abnormal
eating
Compulsions Inappropriate
sexual
Delusions Hallucinations Aphasia Parkinsonism MND
UBC1 F bvFTD 1 1 1 1 0 0 0 0 0 0
UBC2 F bvFTD 1 0 0 0 1 1 0 0 0 0
UBC3 F bvFTD 1 1 1 0 1 0 0 0 0 0
UBC4 F bvFTD 1 1 1 0 0 0 0 0 0 0
UBC5 M bvFTD 1 1 1 0 1 1 0 0 0 0
UBC6 F bvFTD 1 1 0 0 0 0 1 0 0 0
MUC1 M Dem NA NA NA NA NA NA NA NA NA NA
MUC2 F bvFTD 1 1 0 0 NA NA NA 1 0 0
MUC3 F Dem NA 1 NA NA NA NA NA NA NA NA
MUC4 M bvFTD 1 1 1 1 NA NA NA 1 0 0
MUC5 F bvFTD 0 1 1 0 NA NA NA 1 0 0
MUC6 M bvFTD 1 1 NA NA NA NA NA NA NA NA
MUC7 F bvFTD 1 1 1 0 0 0 0 0 0 0
MUC8 M bvFTD NA 1 NA NA NA NA NA NA NA NA
MUC9 M bvFTD 0 1 1 1 NA NA NA 0 0 0a
UR1 M bvFTD 1 1 1 1 1 0 1 0 0 0
UR2 F bvFTD 1 1 1 0 1 0 0 0 0 0
UR3 F bvFTD 1 NA 1 1 0 1 0 0 0 0
UR4 F bvFTD 1 1 0 1 0 0 0 0 0 0
UT1 M bvFTD NA 1 NA NA NA 1 0 0 0 0
UTSW1 M bvFTD 1 1 1 1 1 0 0 1 0 0
NWU1 M bvFTD 0 1 1 1 1 0 0 0 0 0
NWU2 F bvFTD 1 1 1 1 1 0 0 1 0 0
UP1 F bvFTD 1 1 1 1 0 NA NA 0 0 0
UP2 M bvFTD 1 0 1 1 0 NA NA 0 0 0
UP3 M bvFTD 1 1 NA 1 0 NA NA 0 0 0
UNSW1 F bvFTD NA 1 NA 1 NA 0 0 1 1 0
UNSW2 M bvFTD NA 1 1 0 0 0 0 1 0 0
MC1 M bvFTD 0 1 1 1 1 0 1 0 0 0
MC2 F bvFTD 0 1 NA 1 1 NA NA 0 0 0
MC3 M bvFTD 0 1 1 1 1 0 0 0 0 0
MC4 M bvFTD 1 0 0 1 0 0 0 0 0 0
MC5 M bvFTD 0 1 1 0 1 0 0 0 0 0
UCL1 M bvFTD NA 1 1 NA NA 0 1 NA 0 0
% with
symptom
74 91 81 61 52 18 18 24 3 0
Cases of aFTLD-U were scored for presence of the symptoms indicated
0 absent, 1 present, NA information not available, bvFTD behavioural variant FTD, Dem unspecified dementia, Disinh disinhibition
a One patient exhibited tongue fasciculation, dysphagia and muscle hypotonia but there was insufficient evidence to diagnose MND
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were infrequent and when present, they were typically
limited to mild rigidity or intermittent hyperkinesias. Only
one patient (1/30, 3%) showed classical parkinsonism.
The three FTLD-UPS cases all had an initial diagnosis
of bvFTD. Very little clinical information was available,
but apathy was common to two of these cases as was
parkinsonism.
Discussion
This study describes the first comprehensive collection
of the aFTLD-U subtype of FTLD-FUS. We show that
aFTLD-U has a distinct clinical phenotype characterised by
the behavioural variant FTD syndrome, a young onset of
disease, a high prevalence of psychotic symptoms and a
low prevalence of motor symptoms. FUS pathology
accounted for 92% of cases with ubiquitin-positive, tau-
and TDP-43-negative FTLD showing that it defines the
vast majority of such cases. However, we identified three
FTLD-UPS cases without CHMP2B mutation showing that
while such cases are rare, the FTLD-UPS classification has
not been completely subsumed by CHMP2B mutation
cases or FTLD-FUS.
Of all of the FTLD subtypes, bvFTD is pathologically the
most heterogeneous making it difficult to predict the under-
lying pathology from clinical features in life. This cohort
similarly has an overlapping range of symptoms with other
sporadic and genetic causes of bvFTD. However, psychotic
symptoms are rarely described in other cases of bvFTD [22],
and the presence of delusions and hallucinations in a sub-
stantial proportion of this cohort may help to distinguish them
from other patients. The very low frequency of motor
symptoms may also help define this group of patients.
The mean age of onset of 41.2 years for the aFTLD-U
cases is much lower than that of a previously reported
sporadic FTLD cohort (60.5 years) [4], and therefore, may
help distinguish them from other sporadic FTLD cases. 15/
34 aFTLD-U cases came from two contributing centres,
therefore, it is possible that the results have been biassed by
these cases, which were previously reported to have a low
age of onset [29, 42]. However, the age of onset of these
cases is not significantly different from the other 19 cases
in the study (t test, ns). Furthermore, psychotic symptoms
are evenly distributed between cases from these two cen-
tres (3/7, 42%) and cases from other centres (5/15, 33%)
(Fisher’s exact test, ns).
Only one aFTLD-U case (3%, 1/34) had a positive
family history for FTD: this patient was one of nine sib-
lings, and had one brother who was diagnosed clinically
with ‘Pick’s disease’ at 61 years of age and died at
64 years of age without autopsy. Another brother was
reported to show ‘cognitive changes’ at the age of 64 years.
The patient was negative for FUS mutation, suggesting that
there may be other genetic causes of FTLD-FUS. While
aFTLD-U cases have a distinctive and consistent clinico-
pathological phenotype, FTLD appears to occur sporadi-
cally in the majority of cases. Of the three FTLD-UPS
cases, two had a family history, and one had at least two
relatives affected with the same disease [43]. These cases
were negative for CHMP2B mutations, which suggests
other genetic causes of FTLD-UPS and the possibility of at
least one other unidentified ubiquitinated protein associated
with FTLD. No gender bias was found in any of the groups
studied. A female preponderance was previously reported
in an analysis of a subset of aFTLD-U cases [29]; however,
this was not confirmed in wider analysis.
It has recently been shown that two rare subtypes of
FTLD, NIFID and BIBD have extensive FUS pathology [34,
38]. We did not include NIFID and BIBD cases in this study
as they have been described to have distinct clinical features
to aFTLD-U cases, particularly prominent motor symptoms
[3, 18, 19, 34, 51, 58]. In order to allow comparison of
FTLD-FUS to other FTLD cases, we focussed on one
subtype of FTLD-FUS (aFTLD-U), as it is possible that
FTLD-FUS comprises a clinically heterogeneous group.
However, now that NIFID, BIBD and aFTLD-U have been
shown to have a common underlying pathology, it will be
interesting to directly compare these different FUS entities
in future studies. FUS pathology is also found in polyglu-
tamine expansion diseases including Huntington’s disease
[57], showing that it is not limited to the FTLD-MND
spectrum of diseases. This is similar to tau and TDP-43
pathology, which are pathological hallmarks of different
FTLD subtypes but are also observed in a wide range of
other neurodegenerative diseases. Within the clinical syn-
drome of FTLD, FUS pathology will be an extremely
important tool for the classification of cases which are tau-
and TDP-43- negative, and wider analysis of FTLD-FUS
cases may reveal further subtypes.
In conclusion, the vast majority of cases with tau- and
TDP-43 negative inclusions have FUS pathology, sug-
gesting that FTLD-FUS is an important FTLD subtype.
The opportunity to analyse a large series of aFTLD-U cases
has only been possible through a large multi-centre col-
laboration, with all centres contributing a relatively small
number of cases. This collaborative effort has provided
new insights into the genetic and clinicopathological
spectrum of FTLD-FUS and FTLD-UPS.
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